Loading
Alto Neuroscience, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Jul 2024.
Alto Neuroscience, Inc.: what insiders have been doing
Every trade that managers of Alto Neuroscience, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 11 filings signed by 3 insiders.
The flow runs one way only: 3 sales worth €3.1M, from 1 insider, and no purchase. One trade stands out by size: a sale of €2.6M from Smith Nicholas Conrad, disclosed on 1 October 2026, or 0.21% of market capitalisation.
Compared with its exchange (5,458 companies, median 22 filings), a count of 11 filings is below the norm. Over the whole record (from 2024), the tally stands at 3 purchases and 3 sales.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€170,409
3 ops. · all time
Sell Volume
€3M
3 ops. · all time
Who traded when
BuySaleNicholas Conrad Smith3 sales
Since the insiders bought
- -80.8%Entry US$13.96 · Close at T+365 US$2.68
- -85.5%Entry US$14.11 · Close at T+365 US$2.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Alto Neuroscience, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$38.38.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$21.94
Analyst consensus
10 analystsStrong buy
US$26.00Target US$38.38(+75%)US$55.00
Income statement
EBITDA-US$60.1M
Net income-US$63.2M0.0% margin
Valuation
PER (forward)-6.7x
P/Book3.5x
Beta1.34
Balance sheet & cash
Market capUS$861M
Total debtUS$24M
Free Cash Flow-US$51.8M
Debt / Equity11%
Profitability & ownership
ROE-49.2%
ROA-26.8%
% insiders4.2%
% institutions87.1%
Last declaration on 5 October 2026
Declarations23 total
55,000 shares@ US$2.320.013% mcap3.1% of flowCommon StockSEC:0002009130-26-000006:0
56,455 shares@ US$2.350.0094% mcap3.3% of flowCommon StockSEC:0002009130-26-000004:0
24,056 shares@ US$2.350.0040% mcap1.4% of flowCommon StockSEC:0002009130-26-000004:3
54,375 shares@ US$2.350.0091% mcap3.2% of flowCommon StockSEC:0002009130-26-000004:1
110,830 shares@ US$26.58260.21% mcap73.8% of flowCommon StockSEC:0002009130-26-000004:2
23,170 shares@ US$25.77860.043% mcap15.0% of flowCommon StockSEC:0002009130-26-000004:4
886 shares@ US$26.870.0017% mcap0.6% of flowCommon StockSEC:0002009130-26-000004:5
134,886 shares@ US$26.66100.0% of flowCommonSEC144:0001950047-26-009858
400,000 shares0Common StockSEC:0002007795-26-000006:0
6,227 shares@ US$19.69100.0% of flowCommon StockSEC:0002007795-26-000002:0
2,806 shares@ US$19.6950.1% of flowCommon StockSEC:0002009130-26-000002:0
10,681 shares@ US$12.53100.0% of flowCommon StockSEC:0001415889-24-019488:0
Canonical exit: 7 Oct 2024 (T+90)
1,600 shares@ US$15.8025.0% of flowCommon StockSEC:0001415889-24-009533:0
Canonical exit: 26 Jun 2024 (T+90)
251,881 sharesCommon StockSEC:0000950170-24-026885:0
34,711 shares0Common StockSEC:0001415889-24-006822:0
19,153 shares0Common StockSEC:0001415889-24-006823:0
1,962,995 sharesCommon StockSEC:0000902664-24-001290:0
588,898 sharesCommon StockSEC:0001415889-24-002938:0
11,777 sharesCommon StockSEC:0001415889-24-002934:0
39,259 sharesCommon StockSEC:0001415889-24-002932:0
23,917 sharesCommon StockSEC:0001415889-24-002942:0
7,851 sharesCommon StockSEC:0001415889-24-002936:0
1,563 shares@ US$16.0024.9% of flowCommon StockSEC:0001415889-24-002940:0
Canonical exit: 6 May 2024 (T+90)
23 of 23 declarations
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company listed on the U.S. NYSE under the ticker ANRO, and it operates in the United States. Headquartered in Mountain View, California, the company was founded in 2019 by Amit Etkin, M.D., Ph.D., after more than a decade of clinical research at Stanford. Alto’s core investment case is built around a precision-psychiatry strategy that seeks to move psychiatry away from trial-and-error prescribing toward biomarker-driven treatment selection. For investors, this makes Alto a differentiated, high-upside but execution-sensitive small-cap biotech focused on neuropsychiatric disorders.
The company’s platform, Precision Psychiatry Platform™, combines EEG-based brain biomarkers, neurocognitive assessments, wearable-derived data, and other biological signals to identify the patients most likely to respond to a given therapy. That approach is intended to improve clinical development efficiency and eventually support more personalized treatment options in a therapeutic area where response rates are often modest and heterogeneous. Alto’s pipeline spans multiple major mental-health indications, including treatment-resistant depression (TRD), major depressive disorder (MDD), bipolar depression, and schizophrenia-related cognitive impairment (CIAS). Its programs are branded ALTO-100, ALTO-101, ALTO-300, and ALTO-207.
Read moreShow less
From a competitive standpoint, Alto is trying to carve out a niche at the intersection of psychiatry, biomarkers, and drug development. That is notable because many CNS companies rely primarily on conventional symptom-based development, whereas Alto is explicitly trying to enrich trials with predictive biology. If successful, this could translate into higher clinical hit rates and clearer differentiation versus broader neuropsychiatry peers. The company’s key assets include ALTO-207, a fixed-dose combination of pramipexole and ondansetron for TRD; ALTO-101 for CIAS; ALTO-300 for MDD; and ALTO-100 for bipolar depression.
Recent news has materially improved the visibility of the story. In 2025, Alto acquired ALTO-207 and later accelerated its development following financing activity. In 2026, the company initiated the Phase 2b TRD trial for ALTO-207, reported additional supportive analyses for ALTO-101, and strengthened its balance sheet with a $120 million PIPE in March 2026. As of March 31, 2026, Alto reported approximately $264 million in cash, cash equivalents, and restricted cash, which it said should support planned operations through 2029, including a potential NDA submission for ALTO-207. Overall, Alto Neuroscience remains an innovation-led U.S. psychiatry biotech on the NYSE, with multiple near- and medium-term clinical catalysts that could drive sentiment and valuation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
